US EditionPublished • loading... • Updated
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Summary by WBOC 16
2 Articles
2 Articles
Soligenix (SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
LOS ANGELES, CA - March 19, 2026 (NEWMEDIAWIRE) - Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma has been published in the peer-reviewed journal Expert Opinion on Investigational Drugs, highlighting the therapy’s safety profile, non-mutagenic mechanism and demonstrated ef…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
